Jeremy G. Chadwick Sells 1,383 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

On March 3rd, Jeremy G. Chadwick, the Chief Operating Officer of Kymera Therapeutics, Inc. (NASDAQ:KYMR), sold 1,383 shares of the company’s stock. The shares were sold at an average price of $30.45, leading to a total transaction amount of $42,112.35. Following this sale, Chadwick now owns 67,800 shares of the company, which are valued at approximately $2,064,510. This transaction represents a 2.00% decrease in his overall position. The details of this transaction were filed with the SEC.

Kymera Therapeutics Stock Performance

On the same day, shares of Kymera Therapeutics saw a decline of 3.8%, trading down $1.18 to reach $30.17. The volume for the day was 982,064 shares traded, significantly surpassing the regular trading volume of 578,939. The company's fifty-day moving average stood at $38.81, while the two-hundred day moving average was at $43.66. Over the past year, Kymera Therapeutics has experienced a low of $29.16 and a high of $53.27. The company has a market capitalization of $1.95 billion and a PE ratio of -12.89.

Recent Earnings Report

Kymera Therapeutics recently released its quarterly earnings data on February 27th. The company reported an earnings per share (EPS) loss of $0.88, which falls short of the consensus estimate of a loss of $0.76 by $0.12. The revenue for the quarter was reported at $7.39 million, which was significantly below analysts' anticipation of $14.81 million. The firm's net margin was negative at 191.26%, and the negative return on equity stood at 24.96%. Analysts expect Kymera Therapeutics to post an EPS of -2.79 for the current financial year.

Analyst Ratings

Multiple brokerages have recently provided insights into Kymera Therapeutics’ stock. UBS Group decreased its target price from $80.00 to $74.00, maintaining a "buy" rating for the company. Morgan Stanley raised their price target from $45.00 to $49.00 and maintained an "equal weight" rating. BMO Capital Markets began coverage on the stock, assigning it a "market perform" rating with a target price of $55.00. Meanwhile, Leerink Partners reiterated an "outperform" rating with a price target of $60.00. Additionally, Stephens reaffirmed an "overweight" rating with the same target price of $60.00. Overall, there are three analysts who have rated the stock as a hold, while ten analysts favor a buy rating, and one has given it a strong buy rating. Currently, the consensus rating stands at "Moderate Buy" with an average price target of $56.69.

Institutional Trading Activity

Several large investors have adjusted their positions in Kymera Therapeutics recently. Massachusetts Financial Services Co. MA increased its stake by 11.7% during the third quarter. The firm now holds 453,377 shares worth approximately $21,458,000 after acquiring an additional 47,507 shares. Eventide Asset Management LLC boosted its position by 9.9%, increasing its holdings to 507,902 shares, valued at $24,039,000. Other firms like Intech Investment Management LLC and JPMorgan Chase & Co. also made adjustments to their shares during the same quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative small molecule therapeutics. These therapeutics aim to selectively degrade disease-causing proteins using the body's own natural protein degradation processes. The company is working on several clinical programs, including the IRAK4 program for treating immunology-inflammation diseases and the STAT3 program targeting hematologic malignancies and autoimmune diseases. Additionally, the MDM2 program aims to address hematological malignancies and solid tumors.

stocks, trading, analysts